Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.40 |
| ▸ | NR1I2 | O75469 | 5/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.37 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.37 |
| ▸ | CTSL | P07711 | 1/20 | 0.37 |
| ▸ | CTSS | P25774 | 1/20 | 0.37 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL772487 | 0.94 | LNPEP (0.43) | KCNH2NR1I2CYP3A4SCN5ACTSL | |
| SCHEMBL771927 | 0.92 | KCNH2 (0.41) | KCNH2NR1I2CYP3A4SCN5ACTSL | |
| SCHEMBL771810 | 0.91 | KCNH2 (0.42) | KCNH2NR1I2CYP3A4SCN5ALNPEP | |
| SCHEMBL772772 | 0.90 | KCNH2 (0.41) | KCNH2NR1I2CYP3A4SCN5ACTSL | |
| SCHEMBL772071 | 0.90 | KCNH2 (0.39) | ROCK2KCNH2NR1I2CYP3A4SCN5A | |
| SCHEMBL771672 | 0.90 | KCNH2 (0.42) | ROCK2KCNH2NR1I2CYP3A4SCN5A | |
| SCHEMBL13285980 | 0.90 | KCNH2 (0.41) | KCNH2NR1I2CYP3A4SCN5ACTSL | |
| SCHEMBL774488 | 0.90 | KCNH2 (0.41) | KCNH2NR1I2CYP3A4SCN5ACTSL | |
| SCHEMBL804270 | 0.89 | KCNH2 (0.39) | KCNH2NR1I2CYP3A4SCN5ACTSL | |
| SCHEMBL804254 | 0.89 | KCNH2 (0.43) | KCNH2NR1I2CYP3A4SCN5ACTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-7977331-B1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2011-07-12 | — | — | US | disclosed |
| US-7977331-B1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2011-07-12 | — | — | US | disclosed |
| US-7977331-B1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2011-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | POLI, TERT, ZC3HAV1 | ROCK2 4024/4885KCNH2 3813/4885NR1I2 1189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.